Free tool
FAERS Monitor: Nipent
Last checked: Nov 19, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020122 or its brand name (Nipent, Pentostatin). Reports on generic versions are filed under their own applications.
Reports
1,052
Serious
968
92% of reports
Hospitalization
431
Death reported
257
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- neutropenia78
- pyrexia72
- dyspnoea71
- diarrhoea62
- drug ineffective62
- off label use59
- pneumonia58
- sepsis57
- nausea55
- anaemia54
- thrombocytopenia54
- febrile neutropenia48
- hypotension47
- renal failure47
- fatigue45
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 21 |
| 2005 | 57 |
| 2006 | 58 |
| 2007 | 46 |
| 2008 | 61 |
| 2009 | 27 |
| 2010 | 39 |
| 2011 | 60 |
| 2012 | 71 |
| 2013 | 74 |
| 2014 | 58 |
| 2015 | 34 |
| 2016 | 21 |
| 2017 | 61 |
| 2018 | 39 |
| 2019 | 63 |
| 2020 | 54 |
| 2021 | 59 |
| 2022 | 26 |
| 2023 | 19 |
| 2024 | 45 |
| 2025 | 38 |
| 2026 | 21 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,107 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| febrile neutropeniaSignal | 48 | 14.5 | 11.0 | 590 |
| neutropeniaSignal | 78 | 11.5 | 9.3 | 740 |
| sepsisSignal | 57 | 10.2 | 7.9 | 467 |
| thrombocytopeniaSignal | 54 | 9.7 | 7.4 | 413 |
| renal failureSignal | 47 | 7.1 | 5.4 | 241 |
| anaemiaSignal | 54 | 5.7 | 4.4 | 204 |
| hypotensionSignal | 47 | 4.7 | 3.5 | 134 |
| pyrexiaSignal | 72 | 4.2 | 3.3 | 173 |
| pneumoniaSignal | 58 | 3.6 | 2.8 | 107 |
| dyspnoeaSignal | 71 | 2.5 | 2.0 | 65 |
| diarrhoea | 62 | 1.9 | 1.5 | 27 |
| nausea | 55 | 1.4 | 1.1 | 6 |
| off label use | 59 | 1.3 | 1.1 | 5 |
| fatigue | 45 | 1.2 | 0.9 | 1 |
| drug ineffective | 62 | 0.9 | 0.7 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.